Latest Conference Articles

Animal models suggest the investigative treatment is safe and tolerable in treating retinal vascular diseases.

There were no significant differences between dexamethasone and fluocinolone acetonide intravitreal implants in controlling inflammation; however, the latter is considered more difficult to use.

A discussion with an investigator on how the SGLT-2 inhibitor may help affected patients.

Up to 77% of patients maintained or improved best-corrected visual acuity at 12 month post-injection.

Hispanic and Black patients with chronic eye diseases had higher odds of missing out on appointments.

Investigators report a low incidence rate of unscheduled or urgent visits within 7 days of injection.

A discussion on the uncovered benefits in risk reduction observed in patients with severe NDPR.

An assessment of VISTA and VIVID patient data uncovered surprising risk factors associated with aflibercept success or failure in DME resolution.

Patients with nAMD, DME, and RVO received fewer intravitreal injections between pre- and post-lockdown periods.

Approximately 30% of schizophrenia patients do not respond to their first treatment.

These findings corroborate similar conclusions presented last year at ARVO.

Age-adjusted glaucoma blindness has nonetheless seen a downward trend between 2000 and 2020.

Andrew J. Cutler, MD discusses new research into the efficacy and safety of a D-ATS treatment in children with ADHD.

Clozapine is considered the gold standard of schizophrenia treatment.

Education could be the best resource in increasing prescription rates for clozapine.

The single-injection investigative gene therapy may help with providing continuous expression of aflibercept.

Data show zolpidem use in 8-week insomnia trial reduced suicidal ideation in patients, even after trial randomization ended.

The AAV8 vector–based gene therapy was associated with improvements in 2 measures of visual function.

An FDA-approved device, provided to eligible patients with age-related macular degeneration, showed ability to detect CNV risks over 5 years.

New data show high rate of depressive symptoms in patients with NTFE schizophrenia.

The majority of patients with a treatment gap longer than 12 weeks had worsening visual acuity, notes a new ARVO study.

The SGLT-2 inhibitor, generally used for cardiometabolic and cardiovascular risk reduction, may provide similar benefits for the ophthalmic disease.

Impaired reward processing could influence the presentation of sleep disturbances for patients with ADHD.

Adults often do not suffer from the symptoms of hyperactivity in ADHD.

New data show adverse childhood experiences can cause personality changes proximal to trauma, rather than developing later in life.

New data show ADHD-specific text message intervention beneficial to patients who may have low rate of stimulant treatment adherence.

While treatment options do not impact 30-day readmissions, they can influence hospital length of stay and costs.

Data show effectiveness of DSRM in treating major depressive disorder with less frequent discontinuations.